Trials / Completed
CompletedNCT06637956
The Effect of Intranasally Administered Nitroglycerin on Hemodynamic Response to Laryngoscopy and Intubation Among Patients Undergoing Coronary Artery Bypass Grafting (CABG) Surgery
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 58 (actual)
- Sponsor
- Muhammad Aamir Latif · Academic / Other
- Sex
- All
- Age
- 35 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
Numerous preventive medications have been used to lessen the cardiovascular response to laryngoscopy and intubation. Though some advantages have been noted, most of these treatments have not been found to be completely satisfying. However, nitroglycerin is the most widely utilized medicine due to its fast effect, short half-life, and absence of sedative qualities.
Detailed description
The circulatory system under compromise is less resilient to the effects of general anaesthesia. Inducing anaesthesia is a crucial step for cardiac patients because their impaired circulatory systems are less tolerant to depression. During coronary artery bypass grafting surgery, the primary objective of general anesthesia is to reduce sympathetic response to uncomfortable stimuli, including laryngoscopy, intubation, skin incision, sternal splitting, and spreading. A rise in blood pressure is one of the hemodynamic reactions that is typically associated with tracheal intubation and laryngoscopy. The impact of intra nasally delivered nitroglycerin on blood pressure response to laryngoscopy and intubation in patients having non-cardiac surgery is currently contentious; however, this study focus on coronary artery bypass grafting surgery patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nitroglycerin (NTG) | Received 1 mg of nitroglycerin intranasally two minutes prior to laryngoscopy and intubation |
Timeline
- Start date
- 2024-01-01
- Primary completion
- 2024-06-30
- Completion
- 2024-06-30
- First posted
- 2024-10-15
- Last updated
- 2024-10-15
Locations
1 site across 1 country: Pakistan
Source: ClinicalTrials.gov record NCT06637956. Inclusion in this directory is not an endorsement.